comprehensive -WSS

comprehensive

author：comprehensive 2025-08-12 06:42:14 - browse：3344

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Doctors on social media are being harassed and cyberbullied

WSS

ACIP vaccine advisory panel sees its vacancies filled

How to fix the rural physician shortage in the U.S.

Inside the rise of 'mukbang' eating videos

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Mom launches Girl Scout troop for LGBTQ youth in Texas

Bernie Sanders gets little from pharma CEOs on drug prices

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress must protect the remaining independent doctors

Tori Bowie and the unacceptable rates of Black maternal death

Eli Lilly’s Mounjaro succeeds in second weight

23andMe had bad news about my health. I wish a person had delivered it

Timeline: Key moments in fight for gay rights

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mom launches Girl Scout troop for LGBTQ youth in Texas

Dobbs anniversary: the lost opportunity of abortion as health care

The thinking behind the controversial eating disorder chatbot Tessa

explore

Biden administration plans revamp of organ transplant system

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Abbott's new heart device gets FDA advisory panel nod

Why Eli Lilly’s earnings didn’t quite live up to the hype

Novo pauses ads for weight loss drug Wegovy amid demand

Why don't Americans have at

Wikipedia

hotspot

hotspot

entertainment